Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
No one on the platform currently holds FUSN.
No tracked institution reports a position in FUSN as of their last filing.
No one on the platform has traded FUSN yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$LXRX It’s been a month and as a reminder; $FUSN 2.0
View on StockTwits ↗
@Impatient_Investor Look at my past posts on $RGLS and $FUSN. No daydreaming there, only hard profitable reality and that certainly beats earning 20$ an hour bashing promising biotech companies like you do! I’ve been doing this for 20 years and done very well so far. You?
View on StockTwits ↗@Impatient_Investor Recently: $RGLS a few weeks ago. (X7 with another x7 CVR) $FUSN last year (x10 with a x1 CVR) Both were extraordinarily lucrative. And look at my previous post (before the buyouts!). They more than make up for the lemons. $DTIL is in my opinion another one that will potentially go up x10
View on StockTwits ↗
$VRDN Went Down to $12s, then Ran Up to $25s (42%+ GAIN, 9+ Mths) $SLDB Ran to $15 (100% Profit, 2Mths) $FUSN BO at $21+ (less then 2Mths, $10 per share profit) Perceptive Advisors, that they are👈👀🦏
View on StockTwits ↗
$RADX New Radiopharm company on Nasdaq backed by Lantheus and in collaborations with MD Anderson- $36 million market cap. Lantheus just bought shares at 150% premium. $RYZB $FUSN
View on StockTwits ↗
@SteveTexans @thompske @AboveTheHorizon and I did with $FUSN the day before it got bought out.
View on StockTwits ↗
$FUSN Been out of this stock for awhile I can’t even remember how much it was when it converted
View on StockTwits ↗
@salmonbrain Sorry I misread your message. In 2024, they went 3 for 5. The mean return was 75.2% while the median return was 85.8%. The 2024 picks included $FUSN, $NAMS, $KRYS, $IONS and $CABA. The respective returns were 292.5%, 104.9%, 85.8%, -30.8% and -76.2%.
View on StockTwits ↗
Blair’s 2024 top pick was $FUSN which was bought by AstraZeneca
View on StockTwits ↗
$FUSN Obviously they are doing something right now that AZ is involved. So exciting. Enjoy the ride Longs. Be well. Crazy K
View on StockTwits ↗$FUSN I’m going to wait a few years. Need to really educate myself here. Hope they have plenty of success with drug. I guess Canada Pension Plan has money to burn. I don’t. I’m just trying to pay my monthly bills. Delusional Kenny
View on StockTwits ↗
$ICCM I've only ever held stock in 1 company that went through the roof overnight and that was Fusion Pharmaceuticals $FUSN .. That was a great day. Hopefully this will do the same.
View on StockTwits ↗
$MNPR Monopar’s MNPR101-Lu mechanism of action is just like Pluvicto (Top Novartis Radiopharm Drug) and same lutetium-177 warhead. Could take Monopar from $15 million market cap to $1.5 billion. Company barely spends any money and float is small. Diamond in the rough. https://m.youtube.com/watch?v=a4e0NsEbk_U $FUSN $RYZB $CATX
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $11M | +1939.6% | $-1.59 | $-2.01–$-1.37 | — | 4 |
| 2027 | $18M | +63.6% | $-1.59 | $-1.59–$-1.59 | — | 1 |
| 2028 | $140M | +673.7% | $-0.78 | $-0.78–$-0.78 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2024-05-07 | $-0.38 | $-0.40 | -5.3% |
| 2024-03-20 | $-0.34 | $-0.39 | -14.7% |
| 2023-11-07 | $-0.40 | $-0.25 | +37.5% |
| 2023-08-08 | $-0.39 | $-0.38 | +2.6% |
| 2023-05-11 | $-0.29 | $-0.45 | -55.2% |
| 2023-03-16 | $-0.57 | $-0.55 | +3.5% |
| 2022-11-08 | $-0.52 | $-0.55 | -5.8% |
| 2022-08-09 | $-0.53 | $-0.44 | +17.0% |
| $2.1B |
| — |
| CINCCinCor Pharma, Inc. | $29.06 | +0.00% | $1.3B | — |
| CTICCTI BioPharma Corp. | $9.10 | +0.06% | $1.2B | — |
Source: Financial Modeling Prep · peers by sector/industry